FDA Grants Niagen Rare Pediatric Disease Designation for Experimental A-T Therapy

Rare Daily Staff

The U.S. Food and Drug Administration has granted Niagen Bioscience Rare Pediatric Disease (RPD) designation for its experimental therapy NB4168 as a potential treatment for ataxia telangiectasia (A-T), a rare inherited neurodegenerative disorder with no approved therapies.

The European Medicines Agency has also awarded Orphan Medicinal Product Designation (OMPD) to NB4168.

A-T is caused by mutations in the ATM gene and typically presents in early childhood, leading to progressive loss of motor coordination, immune dysfunction, increased cancer risk, and premature aging.

NB4168 is an oral small molecule designed to increase systemic exposure to nicotinamide riboside (NR), a precursor to NAD+, a coenzyme involved in DNA repair, mitochondrial function, and cellular stress responses. These pathways are disrupted in A-T, providing a biological rationale for targeting NAD+ metabolism.

The dual regulatory designations provide development incentives, including potential regulatory support and, in the United States, eligibility for a priority review voucher upon approval. They also reflect regulatory recognition of both the severity of A-T and the lack of available treatments.

NB4168 is the first candidate to emerge from Niagen Bioscience’s pharmaceutical subsidiary, NAD Pharmaceuticals Corp., which was recently established to focus on rare genetic diseases and age-related conditions. The company is currently conducting preclinical studies and plans to submit an investigational new drug application to initiate human trials.

External experts note that NAD+ depletion is implicated in multiple hallmarks of A-T, including impaired DNA damage repair and mitochondrial dysfunction, suggesting that boosting intracellular NAD+ could represent a novel therapeutic approach not only for A-T but potentially for other accelerated aging disorders.

While still in early development, NB4168’s progress will be closely watched as a test case for whether NAD+-modulating strategies can translate from consumer health products into clinically meaningful therapies for rare diseases.

“Receiving RPD designation from the FDA and OMPD from the EMA represents meaningful regulatory validation of NB4168 and our strategy to develop therapies for patients with serious rare diseases,” said Rob Fried, CEO of Niagen Bioscience. “These milestones strengthen our path toward clinical development and reinforce the opportunity to extend our leadership in NAD+ science into regulated medicines.”

Photo: Rob Fried, CEO of Niagen Bioscience.